Cargando…

O5.5. THE NEUROBIOLOGY OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: MULTI-MODAL PET AND FMRI FINDINGS

BACKGROUND: The neurobiological mechanisms underlying anhedonia and other negative symptoms in schizophrenia are unknown. Understanding this would help identify treatments for these symptoms. Pre-clinical and human evidence shows the mu-opioid receptor plays a key role in reward processing and anhed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Howes, Oliver, Ashok, Abhishekh, Shatalina, Ekaterina, Rabiner, Eugenii, Reis Marques, Tiago
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Oral Session: Digital Health/Methods
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234168/ http://dx.doi.org/10.1093/schbul/sbaa028.028

Ejemplares similares

O11.3. SYNAPTIC MARKER PROTEIN SV2A IS REDUCED IN SCHIZOPHRENIA IN VIVO AND UNAFFECTED BY ANTIPSYCHOTICS IN RATS
por: Chika Onwordi, Ellis, et al.
Publicado: (2020)

Reward processing in schizophrenia and its relation to Mu opioid receptor availability and negative symptoms: A [(11)C]-carfentanil PET and fMRI study
por: Shatalina, Ekaterina, et al.
Publicado: (2023)

Reduced mu opioid receptor availability in schizophrenia revealed with [(11)C]-carfentanil positron emission tomographic Imaging
por: Ashok, Abhishekh H., et al.
Publicado: (2019)

O5.3. IMPAIRED LEFT TEMPORAL-PARIETAL JUNCTION FMRI ACTIVITY DURING CATEGORY FLUENCY IN FIRST-EPISODE PSYCHOSIS
por: Perumaly, Leana, et al.
Publicado: (2020)

O4.6. REAL-TIME FMRI NEUROFEEDBACK FOR TREATMENT REFRACTORY HALLUCINATIONS IN SCHIZOPHRENIA
Publicado: (2020)

O5.1. STRIATAL DOPAMINE AND REDUCED REWARD PREDICTION ERROR SIGNALING IN UNMEDICATED SCHIZOPHRENIA PATIENTS
por: Katthagen, Teresa, et al.
Publicado: (2020)

O11.5. INCREASED INFLAMMATION AND MACROPHAGE INFILTRATION IS ASSOCIATED WITH ALTERED SUBEPENDYMAL ZONE NEUROGENESIS IN SCHIZOPHRENIA BUT NOT BIPOLAR DISORDER
por: North, Hayley, et al.
Publicado: (2020)

O2.5. CORTICAL PATTERNING OF ABNORMAL MORPHOMETRIC SIMILARITY IN PSYCHOSIS IS ASSOCIATED WITH BRAIN EXPRESSION OF SCHIZOPHRENIA-RELATED GENES
Publicado: (2020)

O3.5. EARLY TRAJECTORIES OF POSITIVE SYMPTOMS REMISSION IN FIRST EPISODE-PSYCHOSIS: A 2-YEAR FOLLOW-UP STUDY
por: Percie du Sert, Olivier, et al.
Publicado: (2020)

O1.5. CLUSTERING-BASED BEHAVIOURAL PHENOTYPES OF INTRINSIC MOTIVATION IN SCHIZOPHRENIA DETERMINED USING OBJECTIVELY QUANTIFIED REAL-WORLD PERFORMANCE
por: Siddiqui, Ishraq, et al.
Publicado: (2020)

O4.4. REAL TIME FMRI NEUROFEEDBACK TARGETING STG AND DMN REDUCES AUDITORY HALLUCINATIONS
por: Niznikiewicz, Margaret, et al.
Publicado: (2020)

O2.6. DELUSIONS ASSOCIATED WITH ABNORMAL FRONTOSTRIATAL EFFECTIVE CONNECTIVITY IN A SPECTRAL DCM ANALYSIS OF RESTING STATE FMRI
por: Okuneye, Victoria, et al.
Publicado: (2020)

O5.2. CBD MODULATION OF HIPPOCAMPAL GLUTAMATE IN PSYCHOSIS
por: O’Neill, Aisling, et al.
Publicado: (2020)

O5.4. THALAMIC CONNECTIVITY IN EARLY PSYCHOSIS DURING TASK AND AT REST
por: Berge, Daniel, et al.
Publicado: (2020)

O7.5. STANDARDIZED MORTALITY RATIOS IN EARLY- AND ADULT ONSET FOR THREE DISORDERS
por: Lammers Vernal, Ditte, et al.
Publicado: (2020)

O4.5. LONG TERM EFFECTS OF EARLY INTERVENTION SERVICES FOR FIRST EPISODE PSYCHOSIS: OUTCOMES OVER FIVE YEARS FROM THE RECOVERY AFTER A 1ST EPISODE OF SCHIZOPHRENIA-EARLY TREATMENT PROGRAM (RAISE-ETP)
por: Robinson, Delbert, et al.
Publicado: (2020)

O5.6. ADVANCED DIFFUSION IMAGING IN PSYCHOSIS RISK: A CROSS-SECTIONAL AND LONGITUDINAL STUDY OF WHITE MATTER DEVELOPMENT
por: Di Biase, Maria, et al.
Publicado: (2020)

O9.5. NORMALIZATION OF DISTURBANCES IN PREDICTION ERROR IS RELATED TO TREATMENT RESPONSE AND RELATED TO THALAMIC GLUTAMATE LEVELS IN NON-RESPONDERS
por: Tangmose, Karen, et al.
Publicado: (2020)

O8.5. SIGNS OF ADVERSITY - A NOVEL MACHINE LEARNING APPROACH TO CHILDHOOD TRAUMA, BRAIN STRUCTURE AND CLINICAL PROFILES
por: Popovic, David, et al.
Publicado: (2020)

O10.5. CLINICAL HIGH RISK (CHR) CRITERIA IN CHILDREN AND ADOLESCENTS NOT SUSPECTED TO DEVELOP PSYCHOSIS: NO TRANSDIAGNOSTIC SEVERITY MARKER OF MENTAL HEALTH PROBLEMS
por: Schultze-Lutter, Frauke, et al.
Publicado: (2020)

O6.5. JUMPING TO CONCLUSIONS ABOUT DECISION NOISE? A COMPUTATIONAL ANALYSIS OF THE RELATIONSHIP BETWEEN BELIEF UPDATING AND PSYCHOTIC SYMPTOMS IN A LARGE UK BIRTH COHORT
por: Croft, Jazz, et al.
Publicado: (2020)

O7.1. ASSOCIATION BETWEEN PATTERNS OF COMORBID MENTAL DISORDERS AND MORTALITY-RELATED ESTIMATES. A NATIONWIDE, REGISTER-BASED COHORT STUDY BASED ON 7.5 MILLION INDIVIDUALS LIVING IN DENMARK
por: Plana-Ripoll, Oleguer, et al.
Publicado: (2020)

O11.4. INTERACTOME OVERLAP BETWEEN SCHIZOPHRENIA AND COGNITION
por: Koch, Elise, et al.
Publicado: (2020)

O11.2. ELEVATION OF MACROPHAGE-RELATED TRANSCRIPTS IN THE MIDBRAIN IN SCHIZOPHRENIA
por: Purves-Tyson, Tertia, et al.
Publicado: (2020)

O2.4. FUNCTIONAL CONNECTOME-WIDE ASSOCIATIONS OF SCHIZOPHRENIA POLYGENIC RISK
por: Cao, Hengyi, et al.
Publicado: (2020)

O2.1. LOCAL AND LONG-RANGE CONNECTIVITY PATTERNS OF AUDITORY PERCEPTUAL DISTURBANCE IN SCHIZOPHRENIA
por: Hare, Stephanie, et al.
Publicado: (2020)

O6.2. A NETWORK FOR COGNITIVE, MOTOR, AND PSYCHOPATHOLOGICAL ALTERATIONS IN SCHIZOPHRENIA SPECTRUM DISORDERS
por: Moura, Bernardo, et al.
Publicado: (2020)

O1.4. HOW THE MOST CITED RESEARCH ARTICLES ABOUT SCHIZOPHRENIA IN 2018 DEPICT THE DISEASE?
por: Tonsig, Gabriela, et al.
Publicado: (2020)

O9.7. TECHNOLOGY ASSISTED RELAPSE PREVENTION PROGRAM REDUCES HOSPITALIZATION IN SCHIZOPHRENIA PATIENTS AT HIGH RISK FOR RELAPSE
por: Schooler, Nina, et al.
Publicado: (2020)

O3.1. CLUSTER ANALYSIS FINDS THREE CLINICALLY-RELEVANT SUBGROUPS OF TRAIT EMOTIONAL EXPERIENCE IN SCHIZOPHRENIA OUTPATIENTS
por: Cowan, Henry, et al.
Publicado: (2020)

O4.2. THE PREVENTION OF RELAPSE AND HOSPITALIZATION IN FIRST EPISODE AND EARLY PHASE SCHIZOPHRENIA: RESULTS FROM THE PRELAPSE TRIAL
por: Kane, John, et al.
Publicado: (2020)

O11.1. MULTIPLE GENOMIC MEASURES OF SCHIZOPHRENIA RISK ARE RELATED TO CORTICAL THICKNESS IN TYPICALLY DEVELOPING YOUTH AND YOUNG ADULTS
por: Jalbrzikowski, Maria, et al.
Publicado: (2020)

O8.1. ASSOCIATION BETWEEN GENETIC AND ENVIRONMENTAL RISK FOR SCHIZOPHRENIA DURING UPBRINGING: FINDINGS FROM A LONGITUDINAL COHORT STUDY
por: Newbury, Joanne, et al.
Publicado: (2020)

O6.3. ASSOCIATIONS BETWEEN COGNITIVE FUNCTION AND CORTICAL LEVELS OF GLUTAMATE AND GABA IN ANTIPSYCHOTIC-NAïVE PATIENTS WITH SCHIZOPHRENIA OR PSYCHOSIS
por: Bojesen, Kirsten, et al.
Publicado: (2020)

O1.6. AFFECTIVE DETERMINANTS OF LIFE-SPACE THROUGH GPS AND ECOLOGICAL MOMENTARY ASSESSMENT IN SCHIZOPHRENIA: WHAT GETS PEOPLE OUT OF THE HOUSE?
por: Parrish, Emma, et al.
Publicado: (2020)

O4.3. SHARED AND DIFFERENTIAL NEUROCOGNITIVE EFFECTS COMPARING HIGH-INTENSITY INTERVAL TRAINING AND ACTIVE VIDEO-GAMING IN SCHIZOPHRENIA – RESULTS FROM AN RCT
por: Bang-Kittilsen, Gry, et al.
Publicado: (2020)

O4.1. AEROBIC EXERCISE DOSE DETERMINES THE COGNITIVE GAIN IN FIRST-EPISODE SCHIZOPHRENIA, SO HOW DO WE ENCOURAGE SUFFICIENT EXERCISE?
por: Nuechterlein, Keith, et al.
Publicado: (2020)

O9.3. CANNABIS CONSUMPTION INCREASES RISK OF PSYCHOSIS IN A SUBGROUP OF PATIENTS WITH HIGH PERIPHERAL BLOOD INFLAMMATION
por: Corsi-Zuelli, Fabiana, et al.
Publicado: (2020)

Specific and non-specific binding of a tracer for the translocator-specific protein in schizophrenia: an [11C]-PBR28 blocking study
por: Marques, Tiago Reis, et al.
Publicado: (2021)

Adenosine A(2A) receptor in schizophrenia: an in vivo brain PET imaging study
por: Marques, Tiago Reis, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f1ua92mviec61ircjdjm575jug